We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker to Buy Oncovision's Preclinical Imaging Business
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) , a major player in the field of preclinical imaging, recently entered into an agreement to acquire Oncovision’s preclinical PET (Positron Emission Tomography) imaging business. Oncovision is a leading provider of innovative medical imaging devices and applications for cancer diagnosis. However, the financial terms of the deal have been kept under wraps.
The deal is expected to close by the fourth quarter of 2016, subject to certain conditions. Notably, the deal excludes Oncovision’s clinical human imaging business, including MAMMI PET, a breast cancer diagnostic device based on PET imaging.
This is not the first collaboration for Bruker and Oncovision. Over the past five years, the companies have been working on an exclusive marketing agreement for Albira PET/SPECT/CT systems for animal imaging. The companies have developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity. Albira Si is the next generation of molecular vision technology, which is strong, flexible and easier to use.
Oncovision and Bruker have also collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system, which is an advanced technology for better preclinical investigation.
Bruker’s management believes that the imaging business buyout will strengthen its clinical imaging division and boost the company’s operating efficiency in this segment. Oncovision, in close collaboration with molecular imaging institute I3M and the University of Valencia, has developed Silicon photomultiplier(SiPM) PET technology and products which render outstanding spatial resolution across the full field of view (FOV) and raise the high-resolution view compared to the earlier PET versions.
This PET technology by Oncovision facilitates clearer image detections. Bruker believes that this modern technology will revolutionize translational research imaging helping Bruker to add more features to its existing and best performing SiPM-PET/SPECT/CT and integrated SiPM-PET/MR imaging systems.
Bruker has been witnessing weak growth in its preclinical imaging division for quite some time now. Meanwhile, the company is poised to strengthen this particular segment through the buyout. The combined resources of both the companies will help increase development and innovation in the domain of molecular imaging technologies. It will also fulfill the rising demand from translational scientists. Bruker will be able to create a more unique portfolio of molecular imaging technologies and offer high-value imaging solutions.
Zacks Rank & Key Picks
Bruker currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are GW Pharmaceuticals plc , NuVasive, Inc. and Quidel Corp. (QDEL - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bruker to Buy Oncovision's Preclinical Imaging Business
Bruker Corporation (BRKR - Free Report) , a major player in the field of preclinical imaging, recently entered into an agreement to acquire Oncovision’s preclinical PET (Positron Emission Tomography) imaging business. Oncovision is a leading provider of innovative medical imaging devices and applications for cancer diagnosis. However, the financial terms of the deal have been kept under wraps.
The deal is expected to close by the fourth quarter of 2016, subject to certain conditions. Notably, the deal excludes Oncovision’s clinical human imaging business, including MAMMI PET, a breast cancer diagnostic device based on PET imaging.
This is not the first collaboration for Bruker and Oncovision. Over the past five years, the companies have been working on an exclusive marketing agreement for Albira PET/SPECT/CT systems for animal imaging. The companies have developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity. Albira Si is the next generation of molecular vision technology, which is strong, flexible and easier to use.
BRUKER CORP Price
BRUKER CORP Price | BRUKER CORP Quote
Oncovision and Bruker have also collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system, which is an advanced technology for better preclinical investigation.
Bruker’s management believes that the imaging business buyout will strengthen its clinical imaging division and boost the company’s operating efficiency in this segment. Oncovision, in close collaboration with molecular imaging institute I3M and the University of Valencia, has developed Silicon photomultiplier (SiPM) PET technology and products which render outstanding spatial resolution across the full field of view (FOV) and raise the high-resolution view compared to the earlier PET versions.
This PET technology by Oncovision facilitates clearer image detections. Bruker believes that this modern technology will revolutionize translational research imaging helping Bruker to add more features to its existing and best performing SiPM-PET/SPECT/CT and integrated SiPM-PET/MR imaging systems.
Bruker has been witnessing weak growth in its preclinical imaging division for quite some time now. Meanwhile, the company is poised to strengthen this particular segment through the buyout. The combined resources of both the companies will help increase development and innovation in the domain of molecular imaging technologies. It will also fulfill the rising demand from translational scientists. Bruker will be able to create a more unique portfolio of molecular imaging technologies and offer high-value imaging solutions.
Zacks Rank & Key Picks
Bruker currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are GW Pharmaceuticals plc , NuVasive, Inc. and Quidel Corp. (QDEL - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>